Cargando…

A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma

AIMS: GSK3511294 is a humanized anti‐interleukin (IL)‐5 monoclonal antibody (mAb) engineered for extended half‐life and improved IL‐5 affinity versus other anti‐IL‐5 mAbs. This study examined its safety, tolerability, pharmacokinetics (PK) and effect on blood eosinophil counts. METHODS: This was a d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Fuhr, Rainard, Bird, Nicholas P., Mole, Sarah, Hardes, Kelly, Man, Yau Lun, Cahn, Anthony, Yancey, Steven W., Pouliquen, Isabelle J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290054/ https://www.ncbi.nlm.nih.gov/pubmed/34292606 http://dx.doi.org/10.1111/bcp.15002

Ejemplares similares

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Efficacy, safety, and tolerability of once‐daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7‐day, crossover study
por: Beier, Jutta, et al.
Publicado: (2017)

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti–interleukin 5 monoclonal antibody, in healthy Japanese male subjects
por: Tsukamoto, Naohiro, et al.
Publicado: (2015)

The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
por: Singh, Dave, et al.
Publicado: (2010)

The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review
por: Patterson, Megan F, et al.
Publicado: (2015)

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial
por: Brown, Mary N., et al.
Publicado: (2019)

Anti‐IL‐7 receptor α monoclonal antibody (GSK2618960) in healthy subjects – a randomized, double‐blind, placebo‐controlled study
por: Ellis, Joanne, et al.
Publicado: (2018)

A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects
por: Shin, Donghoon, et al.
Publicado: (2015)

A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects
por: Lee, Hyun A, et al.
Publicado: (2022)

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma
por: Portnoy, Alison, et al.
Publicado: (2013)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler
por: Lähelmä, Satu, et al.
Publicado: (2015)

Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients
por: Cramer, Steven C., et al.
Publicado: (2017)

Histological remission of eosinophilic esophagitis under asthma therapy with IL-5 receptor monoclonal antibody: A case report
por: Huguenot, Marc, et al.
Publicado: (2022)

Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study
por: Liao, Karen, et al.
Publicado: (2021)

Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma
por: Ma, Linlin, et al.
Publicado: (2022)

Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports
por: Skouvaklidou, Elpida, et al.
Publicado: (2023)

Development of a real-world database for asthma and COPD: The SingHealth-Duke-NUS-GSK COPD and Asthma Real-World Evidence (SDG-CARE) collaboration
por: Lam, Sean Shao Wei, et al.
Publicado: (2023)

A Cocktail Interaction Study Evaluating the Drug‐Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels
por: Treijtel, Nicoline, et al.
Publicado: (2019)

Investigating the contribution of IL-17A and IL-17F to the host response during Escherichia coli mastitis
por: Roussel, Perrine, et al.
Publicado: (2015)

Peripheral Blood MDSCs, IL-10 and IL-12 in Children with Asthma and Their Importance in Asthma Development
por: Zhang, Yan-Li, et al.
Publicado: (2013)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Dual Monoclonal Antibody Therapy for a Severe Asthma Patient
por: Domingo, Christian, et al.
Publicado: (2020)

IL-22 Is Deleterious along with IL-17 in Allergic Asthma but Is Not Detrimental in the Comorbidity Asthma and Acute Pneumonia
por: Goulart, Amanda, et al.
Publicado: (2023)

Girdin acts as an oncogene in gastric cancer by regulating AKT/GSK3β/β-catenin signaling
por: Wang, Yun, et al.
Publicado: (2023)

Depletion of LAG‐3(+) T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781
por: Ellis, Joanne, et al.
Publicado: (2020)

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma
por: Farahani, Rahim, et al.
Publicado: (2014)

GSK3β inhibition attenuates LPS-induced IL-6 expression in porcine adipocytes
por: Wang, Linjie, et al.
Publicado: (2018)

Asthma in pregnancy: association of asthma control test (ACT) with clinical management by the global initiative for asthma (GINA)
por: Araujo, Georgia, et al.
Publicado: (2015)

Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway
por: Ng, Lui, et al.
Publicado: (2018)

Systemic IL-6 and Severe Asthma
por: Lipworth, Brian, et al.
Publicado: (2020)

GSK-3β and ERK1/2 incongruously act in tau hyperphosphorylation in SPS-induced PTSD rats
por: Wei, Zhen, et al.
Publicado: (2019)

Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)

Opuntia humifusa modulates morphological changes characteristic of asthma via IL-4 and IL-13 in an asthma murine model
por: Lee, Soon-Young, et al.
Publicado: (2017)

Novel Reporter Alleles of GSK-3α and GSK-3β
por: Barrell, William B., et al.
Publicado: (2012)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

Anti-IL5 therapy for asthma and beyond
por: Mukherjee, Manali, et al.
Publicado: (2014)

Potential Involvement of IL-17F in Asthma
por: Ota, Kyoko, et al.
Publicado: (2014)

Pharmacological Rationale for Targeting IL-17 in Asthma
por: Rahmawati, Siti Farah, et al.
Publicado: (2021)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Pouliquen, I. J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7fcgbqdfpjrjjcbqapfb2h1cvt